Ascentage Pharma Group International (AAPG) Current Deferred Revenue: 2023-2024
Historic Current Deferred Revenue for Ascentage Pharma Group International (AAPG) over the last 2 years, with Dec 2024 value amounting to $5.1 million.
- Ascentage Pharma Group International's Current Deferred Revenue was N/A to $5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $5.1 million for FY2024, which is 97.96% down from last year.
- Per Ascentage Pharma Group International's latest filing, its Current Deferred Revenue stood at $5.1 million for FY2024, which was down 97.96% from $251.2 million recorded in FY2023.
- In the past 5 years, Ascentage Pharma Group International's Current Deferred Revenue registered a high of $251.2 million during FY2023, and its lowest value of $5.1 million during FY2024.
- For the 2-year period, Ascentage Pharma Group International's Current Deferred Revenue averaged around $128.2 million, with its median value being $128.2 million (2023).
- Data for Ascentage Pharma Group International's Current Deferred Revenue shows a maximum YoY plummeted of 97.96% (in 2024) over the last 5 years.
- Over the past 2 years, Ascentage Pharma Group International's Current Deferred Revenue (Yearly) stood at $251.2 million in 2023, then crashed by 97.96% to $5.1 million in 2024.